| Translation control: bridging the gap between genomics and proteomics? B Pradet-Balade, F Boulmé, H Beug, EW Müllner, JA Garcia-Sanz Trends in biochemical sciences 26 (4), 225-229, 2001 | 496 | 2001 |
| Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors C Leberbauer, F Boulmé, G Unfried, J Huber, H Beug, EW Müllner Blood 105 (1), 85-94, 2005 | 242 | 2005 |
| Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays H Dolznig, F Boulmé, K Stangl, EM Deiner, W Mikulits, H Beug, ... The FASEB Journal 15 (8), 1442-1444, 2001 | 120 | 2001 |
| Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription F Boulmé, F Freund, S Litvak, S Moreau, PE Nielsen, S Gryaznov, ... Nucleic acids research 26 (23), 5492-5500, 1998 | 81 | 1998 |
| Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA B Mestre, A Arzumanov, M Singh, F Boulmé, S Litvak, MJ Gait Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1445 (1 …, 1999 | 50 | 1999 |
| Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA–tRNALys3 duplex F Freund, F Boulmé, S Litvak, L Tarrago-Litvak Nucleic acids research 29 (13), 2757-2765, 2001 | 33 | 2001 |
| Translational control of putative protooncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling M Joosten, M Blázquez-Domingo, F Lindeboom, F Boulmé, ... Journal of Biological Chemistry 279 (37), 38169-38176, 2004 | 28 | 2004 |
| p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: Interactions with primer tRNALys3, initiation of cDNA … E Dufour, RE Dirani‐Diab, F Boulmé, M Fournier, G Nevinsky, ... European journal of biochemistry 251 (1‐2), 487-495, 1998 | 26 | 1998 |
| Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2 F Boulme, M Perälä-Heape, L Sarih-Cottin, S Litvak Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1351 (3 …, 1997 | 18 | 1997 |
| Reliability of mRNA profiling: verification for samples with different complexities B Pradet-Balade, F Boulmé, EW Müllner, JA Garcia-Sanz Biotechniques 30 (6), 1352-1357, 2001 | 16 | 2001 |
| Inhibition of HIV-1 Replication In Vitro and in Human Infected Cells by Modified Antisense Oligonucleotides Targeting the tRNALys3/RNA Initiation Complex F Freund, F Boulmé, J Michel, M Ventura, S Moreau, S Litvak Antisense and Nucleic Acid Drug Development 11 (5), 301-315, 2001 | 13 | 2001 |
| Study of HIV‐2 primer–template initiation complex using antisense oligonucleotides F Boulmé, F Freund, S Gryaznov, PE Nielsen, L Tarrago‐Litvak, S Litvak European Journal of Biochemistry 267 (9), 2803-2811, 2000 | 13 | 2000 |
| Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 or HIV-2 RNAs by both type 1 and 2 reverse transcriptases F Boulmé, F Freund, S Litvak FEBS letters 430 (3), 165-170, 1998 | 10 | 1998 |
| Massive translational repression of gene expression during mouse erythroid differentiation B Pradet-Balade, C Leberbauer, N Schweifer, F Boulmé Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1799 (9), 630-641, 2010 | 1 | 2010 |
| PROTEIN SYNTHESIS, POST-TRANSLATION MODIFICATION, AND DEGRADATION-Translational Control of Putative Protooncogene Nm23-M2 by Cytokines via Phosphoinositide 3-Kinase Signaling. M Joosten, M Blazquez-Domingo, F Lindeboom, F Boulme, ... Journal of Biological Chemistry 279 (37), 38169-38176, 2004 | | 2004 |
| Effet in vitro d'oligonucléotides antisens en série phosphodiester et chimiquement modifiés sur l'étape initiale de la transcription inverse des virus de l'immunodéficience … F Boulmé Bordeaux 2, 1998 | | 1998 |
